Search

May 10, 2018—The statement, accompanied by an editorial, captures the proceedings of the 2017 Leadership Summit on Cybersecurity Vulnerabilities: Communications Strategies for Clinicians and Patients that was attended by patient representatives, subject matter experts, the Heart Rhythm Society (HRS) and American College of Cardiology (ACC) leadership, the U.S. Food and Drug Administration (FDA) and Federal Bureau of Investigation (FBI) officials, and leadership from CIED manufacturers with the goal of developing patient-centered communication strategies for health care professionals, industry, and governmental agencies. The document outlines four key communication themes: when to notify patients, whom to notify, how to communicate with patients, and what elements to discuss with patients. 

November 27, 2017—The 2017 ACC/HRS Lifelong Learning Statement for Clinical Cardiac Electrophysiology Specialists complements the 2015 ACC/AHA/HRS Advanced  Training Statement on clinical cardiac electrophysiology  by focusing on the competencies expected of practicing cardiac electrophysiologists throughout their careers. It also recognizes those competencies that exceed standard expectations and may be achieved and maintained by some cardiac electrophysiologists based on their specific training and practice focus. This document provides examples of appropriate measures for assessing competence in the context of lifelong learning.

July 28, 2007—Amiodarone is commonly used to treat supraventricular and ventricular arrhythmias in various inpatient and outpatient settings. Because of adverse drug reactions, proper use is essential to deriving optimal benefits from the drug with the least risk.

This document has been retired because it is no longer current.

January 2003—The provision of services accompanying technology-based electrophysiological-related interventions created an opportunity for health care professionals to specialize in the field of cardiac rhythm management. Known as allied professionals (APs), this diverse group of nurses, physician assistants, technologists, technicians, and engineers is dedicated to promoting excellence in the care of patients with cardiac rhythm disorders.

This document was reaffirmed on February 7, 2018, and will be formally assessed by February 2023.

February 2002—This Statement gives the revised NBG code, endorsed by the British Pacing and Electrophysiology Group (BPEG) and the North American Society of Pacing and Electrophysiology (NASPE, now known as Heart Rhythm Society) in 2001. This statement is more compatible with contemporary and emerging pacing technology with particular attention to the issue of multisite pacing.

This document was reaffirmed on February 7, 2018, and will be formally assessed by February 2023.

August 2011—Genetic testing is increasingly important in determining potential cardiac conditions in patients and is used in clinical settings more than ever before. To ensure that physicians have up-to-date knowledge of the evolving role of genetic testing for sudden death predisposing, genetic heart diseases in cardiology, which can be lifesaving for some patients, the Heart Rhythm Society and the European Heart Rhythm Association have prepared HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies

This document was reaffirmed on April 11, 2018, and will be formally assessed by April 2023.

July 2011—Developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA) and the Society of Thoracic Surgeons (STS), a diverse panel of experts in pacemaker and defibrillator management focused on medical procedures that might interfere with cardiovascular implantable electronic devices (CIEDs) function.

This document was reaffirmed on March 7, 2018, and will be formally assessed by March 2021.

May 17, 2010—This document was developed in collaboration with and endorsed by the American College of Cardiology (ACC), the American Geriatrics Society (AGS), the American Academy of Hospice and Palliative Medicine (AAHPM), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), and the Hospice and Palliative Nurses Association (HPNA). It focuses on patients nearing the end of life and addresses patients who have made a decision for CIED deactivation at other times, as well as the rights and responsibilities of clinicians (and others, such as industry-employed allied professionals) who may not wish to perform deactivation.

This document was reaffirmed on March 7, 2018, and will be formally assessed by March 2023.

March 20, 2006—Following the recall event in 2005, the Guidant Corporation commissioned an independent panel charged with studying, analyzing, and evaluating the policies and procedure of the cardiac rhythm management (CRM) business with regard to postmarket device surveillance. This report summarizes the findings and recommendations of the panel.

This document has been retired because it is no longer current.